Drugs / Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03579888 | Jun 2020 → May 2021 | B-lymphoblastic leukemia/lymphoma with t(v;11q23.3), B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma +1 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03579888 ↗ |
| Modality | Cell therapy | “CD19 positive (+) specific CAR-T cells” NCT03579888 ↗ |
| Route | Intravenous | “Given IV” NCT03579888 ↗ |
| Target | CD19 | “CD19 positive (+) specific CAR-T cells” NCT03579888 ↗ |